Showing results (181-190 of 225) with videos related to
Sort By:
Pageof 23
British Journal of Haematology|December 19, 1998
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphomaA Younes, J Romaguera, O Mesina, et al.Journal of Biological Regulators and Homeostatic Agents|August 4, 2020
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)P Conti, Al Caraffa, C E Gallenga, et al.Leukemia & Lymphoma|February 26, 1999
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphomaJ E Romaguera, F B Hagemeister, P McLaughlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion scheduleA Younes, J P Ayoub, F B Hagemeister, et al.Metabolites|March 26, 2025
Association Between Coffee Consumption and Metabolic Syndrome Components Among Saudi AdultsWala I Alzahrani, Sarah N Alsharif, Maryam S Hafiz, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes, H A Preti, F B Hagemeister, et al.Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.Leukemia & Lymphoma|June 1, 1997
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphomaA Younes, M A Rodriguez, P McLaughlin, et al.Bone Marrow Transplantation|April 21, 2001
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survivalK van Besien, A Rodriguez, S Tomany, et al.Leukemia & Lymphoma|September 7, 2000
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patientsJ E Romaguera, I F Khouri, H M Kantarjian, et al.Pageof 23